Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocugen Inc (NASDAQ: OCGN) said that it sent a request to the FDA for an emergency authorization for its COVID-19 vaccine candidate BBV152, known as Covaxin outside of the US, for just pediatric use. The vaccine candidate is a whole-virion, inactivated vaccine and recently authorized by the WHO, developed by the Indian Company Bharat Biotech.

Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids

With its chances of experiencing another sharp slide in price likely. If you own OCGN stock today, cash out ASAP to avoid holding the bag.

With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News'

Moderna

Novavax

Multiple earnings reports and regulatory updates shook up the coronavirus vaccine space this week.

Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This Week

The agency will allow vaccine boosters to be mixed and matched.

This Surprising FDA Announcement Could Be Huge for Ocugen

MALVERN, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) --  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen's COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company's partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age.

Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years

Is Ocugen's Surge Much Ado About Nothing?

With high percentage of vaccination in U.S. and Canada, Ocugen has a limited addressable market. With the company still waiting for official FDA approval for the Covaxin, it's advisable for investors to stay away.

Avoid Ocugen — The Vaccine Is Too Little, Too Late

OCGN stock has moved higher despite little evidence anything's changed regarding Ocugen's revenue potential in the U.S. The post Ocugen Neared $16 Yesterday, But I'll Eat 4 Hats If It Gets to $32 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

Ocugen Neared $16 Yesterday, But I'll Eat 4 Hats If It Gets to $32

They say that markets have memories. It's true, and holders and traders of Ocugen, Inc. (NASDAQ:OCGN) may have cause for concern.

BZ Chart Of The Day: Will Ocugen Remember?

WHO's Technical Advisory Group has recommended the Emergency Use Listing status for Bharat Biotech's COVID-19, Covaxin. Read Next:   Ocugen Reverses Course From Monday's Massive Surge As COVID-19 Vaccine Partner Faces WHO Setback.

Ocugen's India Partnered COVID-19 Vaccine Gets WHO Approval: Report

The biotech stock is now up a staggering 756% year to date.

Here's Why Ocugen Stock Skyrocketed 64.9% in October

The WHO has finally given Covaxin emergency approval, putting OCGN stock in the spotlight. Will Ocugen be able to bring doses to the U.S.?

OCGN Stock Alert: WHO Issues Emergency-Use Listing for Covaxin

Cara Therapeutics

Enanta Pharmaceuticals

These biotech stocks have recently been responsible for a slew of rocketship emojis.

3 Explosive Biotech Stocks -- Could They Shoot Even Higher?

MALVERN, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its third quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Tuesday, November 9, 2021.

Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update

A key WHO ruling that could materialize as soon as tomorrow has investors considering where OCGN stock could be headed this week. The post OCGN Stock Alert: Why Ocugen Shares Are Drawing Eyes Ahead of Nov. 3 appeared first on InvestorPlace.

OCGN Stock Alert: Why Ocugen Shares Are Drawing Eyes Ahead of Nov. 3

DexCom

Intuitive Surgical

Are these the top picks in the health care industry right now?

4 Top Health Care Stocks For Your November 2021 Watchlist

Ocugen is forging ahead with its plans for regulatory approval, but that doesn't make OCGN stock any more worthy of your capital. The post An Approval by WHO Would Not Help Ocugen appeared first on InvestorPlace.

An Approval by WHO Would Not Help Ocugen

Investors are excited about a decision that doesn't really benefit Ocugen at this point.

Why Ocugen Stock Will Probably Soar Tomorrow -- but Shouldn't

Ocugen, Inc. (NASDAQ: OCGN) shares are trading higher amid heightened interest in the stock from retail traders on social media. According to SwaggyStocks, Ocugen was the fifth most mentioned stock on Reddit's r/wallstreetbets.

What's Going On With Ocugen's Stock?

Australia just gave a vote of confidence to Covaxin, sending OCGN stock climbing. However, the real catalyst rests in the hands of the WHO.

OCGN Stock Alert: This Covaxin Update Is Sending Ocugen Rallying

Bionano Genomics

Bionano Genomics and Ocugen could both be gearing up for a healthy rally this month.

2 Best Biotech Stocks to Buy in November

Ocuigen is unlikely to be able to get Covaxin widely distributed in the U.S. until Spring 2023. By that time, the shot won't help OCGN stock much if at all.

4 Reasons Why Ocugen Will Make Very Little or No Money From Covaxin

argenx

AstraZeneca

Could these biotech stocks be top buys as investors digest the latest earnings figures?

Best Stocks To Buy This Week? 3 Biotech Names To Know

AMC Entertainment

Camber Energy

Clover Health Investments

Digital World Acquisition Corp

GameStop

Remark Hlds

Retail investors are dropping out of these meme stocks and the hype is fading. These shares are unlikely to reach previous highs again.

7 Meme Stocks to Avoid Like the Plague

Marathon Digital Holdings

Nikola

This trio could deliver jaw-dropping revenue growth over the next three years. However, this doesn't tell the full story.

News for Ocugen, Inc. Stock (OCGN)